Skip to main content
SpringerLink
Log in
Book cover

Cyclin Dependent Kinase (CDK) Inhibitors pp 139–148Cite as

Cyclin-Dependent Kinase Inhibitors and Human Cancer

  • Chapter

Part of the book series: Current Topics in Microbiology and Immunology ((CT MICROBIOLOGY,volume 227))

Abstract

As tumor suppressor candidates, cyclin-dependent kinase (CDK) inhibitors have a simple, aesthetic quality. They act directly on the mechanism that drives cells through mitosis and DNA replication. Elimination of CDK inhibitor activity, by mutation for instance, should release CDKs from this form of regulation and remove one of the restraints on cell growth.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   99.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Cairns P, Proctor AJ, Knowles MA (1993) Initiation of bladder cancer may involve deletion of a tumor suppressor gene on chromosome 9. Oncogene 8: 1083–1085

    PubMed  CAS  Google Scholar 

  • Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, Merlo A, Mao L, Herath J, Jenkins R, Westra W, Rutter JL, Buckler A, Gabrielson E. Tockman M, Cho KR, Hedrick L, Bova GS, Isaacs W, Koch W, Schwab D, Sidransky D (1995) Frequency of homozygous detection at p16/CDKN2 in primary human tumours. Nature Genet 11: 210–212

    Article  PubMed  CAS  Google Scholar 

  • Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, Weinstein CL, Hruban RH, Yeo CJ, Kern SE (1994) Frequent somatic mutations and homozygous deletions of the p16 ( MTSI) gene in pancreatic adenocarcinoma. Nature Genet 8: 27–32

    Article  PubMed  CAS  Google Scholar 

  • Cannon-Albright LA, Goldgar G, Meyer LJ, Lewis CM, Anderson DE, Fountain JW, Hegi ME, Wiseman RW, Petty EM, Bale AE, Olopade 01, Diaz MO, Kwiatkowski DJ, Piepkorn MW, Zone JJ, Skolnick MH (1992) Assignment of a melanoma susceptibility locus, MLM, to chromosome 9p13-p22. Science 258: 1148–152

    Article  PubMed  CAS  Google Scholar 

  • Cannon-Albright LA, Meyer LJ, Goldgar DE, Lewis CM, McWhorter WP, Jost M, Harrison D, Anderson DE, Zone JJ, Skolnick MH (1994) Penetrance and expressivity of the chromosome 9p melanoma susceptibility locus ( MLM ). Cancer Res 54: 6041–6044

    Google Scholar 

  • Dalbagni G, Presti J, Reuter V, Fair WR, Cardon-Cardo C (1993) Genetic alterations in bladder cancer. Lancet 342: 469–471

    Article  PubMed  CAS  Google Scholar 

  • Gonzalez-Zulueta M, Bender CM, Yang AS, Nguyen T, Beart RW, Van Tornout JM, Jones PA (1995) Methylation of the 5’ CpG island of the p16/CDKN2 tumor suppressor gene in normal and a transformed human tissues correlates with gene silencing. Cancer Res 55: 4531–4535

    PubMed  CAS  Google Scholar 

  • Gruis NA, Weaver-Feldhaus J, Liu Q, Frye C, Ecles R, Orlow I, Lacombe L, Ponce-Castoneda V, Lianes P, Latres E, Skolnick M, Cardon Cardo C. Kamb A (1995) Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression. Am J Pathol 146: 1199–1206

    PubMed  CAS  Google Scholar 

  • Guan K-L, Jenkins CW, Li Y, Nichols MA, Wu X, O’Keefe CL, Matera AG, Xiong Y (1994) Growth suppression by p18, a p16INK4,narrsi and p14INK4/M rrsi related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev 8: 2939–2952

    Article  PubMed  CAS  Google Scholar 

  • Hannon GJ, Beach D (1994) p15INK4a is a potential effector of TFG-(3-induced cell cycle arrest. Nature 371: 257–260

    Article  PubMed  CAS  Google Scholar 

  • Healy E, Rehman I, Angus B, Rees JL (1995) Loss of heterozygosity in sporadic primary cutaneous melanoma. Genes Chromosomes Cancer 12: 152–156

    Article  PubMed  CAS  Google Scholar 

  • Herman JG, Merlo A, Mao L, Lapidus RG, Issa JJ-P, Davidson NE, Sidransky D, Bayliin SB (1995) Inactivation of the CDKN2/P 16/MTS 1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 55: 4525–4530

    PubMed  CAS  Google Scholar 

  • Herman JG, Jen J, Merlo A, Baylin SB (1996) Hypermethylation-associated inactivation indicates a tumor suppressor role for p161NK4B Cancer Res 56: 722–727

    PubMed  CAS  Google Scholar 

  • Holland EA, Beaton SC, Becker TM, Grulet OMC, Peters BA, Rizos H, Kefford RF, Mann GJ (1995) Analysis of the p16 gene, CDKN2, in 17 Australian melanoma kindreds. Oncogene 11: 2289–2294

    PubMed  CAS  Google Scholar 

  • Hussussian CJ, Struewing JP, Goldstein A-MN, Higgins PAT, Ally DS, Sheahan MD, Clark WH Jr, Tucker MA, Dracopoli NC (1994) Germline p16 mutations in familial melanoma. Nature Genet 8: 15–21

    Article  PubMed  CAS  Google Scholar 

  • Kamb A (1995) Cell-cycle regulators and cancer. Trends in Genetics 11: 136–140

    Article  PubMed  CAS  Google Scholar 

  • Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS III, Johnson BE, Skolnick MH (1994a) A cell cycle regulator potentially involved in genesis of many tumor types. Science 264: 436–440

    Article  PubMed  CAS  Google Scholar 

  • Kamb A, Shattuck-Eidens D, Eeles R, Liu Q, Gruis NA, Ding W, Hussey C, Tran T, Miki Y, Weaver-Feldhaus J, McClure M, Aitken JF, Anderson DE, Bergman W, Frants R, Goldgar DE, Green A, MacLennan R, Martin NG, Meyer LJ, Youl P, Zone JJ, Skolnick MH, Cannon-Albright LA (1994b) Analysis of CDKN2 (MTSI) as a candidate for the chromosome 9p melanoma susceptibility locus (MLM). Nature Genet 8: 22–26

    Article  CAS  Google Scholar 

  • Koh J, Enders GH, Cynlacht BD, Harlow E (1995) Tumor-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature 375: 506–510

    Article  PubMed  CAS  Google Scholar 

  • Kohn KW, Jackman J, O’Connor PM (1994) Cell cycle and cancer chemotherapy. J Cell Biochem 54: 440–452

    Article  PubMed  CAS  Google Scholar 

  • Kawamata N, Morosetti R, Miller CW, Park D, Spirin KS, Nakamaki T, Takeuchi S, Hatta Y, Simpson J, Wilczynski S, Lee YY, Bartram CR, Koeffler HP (1995) Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. Cancer Res 55: 2266–2269

    PubMed  CAS  Google Scholar 

  • Li Y, Nichols MA, Shay JW, Xiong Y (1994) Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb. Cancer Res 54: 6078–6082

    PubMed  CAS  Google Scholar 

  • Liu Q, Neuhausen S, McClure M, Frye C, Weaver-Feldhaus J, Gruis NA, Eddington K, Allalunis-Turner MJ, Skolnick MH, Fujimura FK, Kamb A (1995) CDKN2(MTSI) tumor suppressor gene mutations in human tumor cell lines. Oncogene 10: 1061–1067

    PubMed  CAS  Google Scholar 

  • Lukas J, Parry D, Aagaard L, Mann DJ, Bartkova J, Strauss M, Peters G, Bartek J (1995) Retinob- lastoma-protein-dependent cell-cycle inhibition by the tumor suppressor p16. Nature 375: 503–506

    Article  PubMed  CAS  Google Scholar 

  • Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D (1995) 5’ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/ MTSI in human cancers. Nature Med 1: 686–691

    Article  PubMed  CAS  Google Scholar 

  • Nakamaki T, Kawamata N, Schwaller J, Tobler A, Fey M, Pakkala S, Lee YY, Kim BK, Fukuchi K, Tsuruoka N, Kahan J, Miller CW, Koeffler HP (1995) Structural integrity of the cyclin-dependent kinase inhibitor genes, p15, p16 and p18 in myeloid leukaemias Br J Haematol 91: 139–149

    Article  PubMed  CAS  Google Scholar 

  • Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA (1994) Deletions of the cyclindependent kinase-4 inhibitor gene in multiple human cancers. Nature 368: 753–756

    Article  PubMed  CAS  Google Scholar 

  • Okamoto A, Hussain SP, Hagiwara K, Spillare EA, Rusin MR, Demetrick DJ, Serrano M, Hannon GJ, Shiseki M, Zariwala M, Xiong Y, Beach DH, Yokota J, Harris CC (1995) Mutations in the p16hNK4/ MTSI/CDKN2, p15INK4B/MTS2, and p18 genes in primary and metastatic lung cancer. Cancer Res 55: 1448–1451

    PubMed  CAS  Google Scholar 

  • Olopade OI, Jenkins R, Linnenbach AJ et al (1990) Molecular analysis of chromosome 9p deletion in human solid tumors. Proc Am Assoc Cancer Res 21: 318

    Google Scholar 

  • Pardee AB, James LJ (1975) Selective killing of transformed baby hamster kidney ( BHK) cells. Proc Natl Acad Sci USA 72: 4994–4998

    Article  PubMed  CAS  Google Scholar 

  • Parry D, Bates S, Mann DJ, Peters G (1995) Lack of cyclin D-Cdk complexes in Rb-negative cells correlates with high levels of p161NK4IMTSI tumour suppressor gene product. EMBO J 14: 503–511

    PubMed  CAS  Google Scholar 

  • Polyak K, Lee M-H, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P, Massague J (1994) Cloning of p27K’PI, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78: 59–66

    Article  PubMed  CAS  Google Scholar 

  • Ranade K, Hussussian CJ, Sikorski RS, Varmus FIE, Goldstein AM, Tucker MA, Serrano M, Hannon GJ, Beach D, Dracopoli NC (1995) Mutations associated with familial melanoma impair p16rN’ 4 function. Nature Genet 10: 114–116

    Article  PubMed  CAS  Google Scholar 

  • Serrano M, Hannon GJ, Beach D (1993) A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366: 704–707

    Article  PubMed  CAS  Google Scholar 

  • Serrano M, Gomez-Lahoz E, DePinho RA, Beach D, Bar-Sagi D (1995) Inhibition of Ras-induced proliferation and cellular transformation by p161Nxa Science 267: 249–252

    Article  PubMed  CAS  Google Scholar 

  • Smith-Sorenson B, Hovig E (1996) CDKN2A (p16°NK4n) somatic and germline mutations. Hum mutat 7: 294–303

    Article  Google Scholar 

  • Stone S, Dayananth P, Jiang P, Weaver-Feldhaus JM, Tavtigian SV, Cannon-Albright L, Kamb A (1995a) Genomic structure, expression and mutational analysis of the p15 (MTS2) gene. Oncogene 11: 987–991

    PubMed  CAS  Google Scholar 

  • Stone S, Jiang P, Dayananth P, Tavtigian SV, Katcher H, Parry D, Peters G, Kamb A (1996) Complex structure and regulation of the p16 (MTSI) locus. Cancer Res 55: 2988–2994

    Google Scholar 

  • Stone S, Dayananth P, Kamb A (1996) Reversible p16-mediated cell cycle arrest as protection from chemotherapy. Cancer Res 56: 3199–3202

    PubMed  CAS  Google Scholar 

  • Toyoshima H, Hunter T (1994) p27, anovel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 78: 67–74

    Article  PubMed  CAS  Google Scholar 

  • Tsai YC, Nichols PW, Hiti AL, Williams Z, Skinner DG, Jones PA (1990) Allelic losses of chromosomes 9,1 1, and 17 in human bladder cancer. Cancer Res 50: 44–47

    PubMed  CAS  Google Scholar 

  • Vidal MJ, Loganzo F, Oliveira AR, Hayward NK, Albino AP (1995) Mutations and defective expression of the WAFI p21 tumor suppressor gene in malignant melanomas. Melanoma Res 5: 243–250

    Article  PubMed  CAS  Google Scholar 

  • Watanabe H, Fukuchi K, Takagi Y, Tomoyasu N, Gomi K (1995) Molecular analysis of the Cipl/Waft (p21) gene in diverse types of human tumors. Biochim Biophys Acta 1263: 275–280

    PubMed  Google Scholar 

  • Zuo L, Weger J, Yang Q, Goldstein AM, Tucker MA, Walker GJ, Hayward N, Dracopoli NC (1996) Germline mutations in the p16°NK4’ binding domain of CDK4 in familial melanoma. Nature Genet 12: 97–99

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Myriad Genetics, Inc, 390 Wakara Way, Salt Lake City, UT, 84108, USA

    A. Kamb

Authors
  1. A. Kamb
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Oncovirology, Department of Molecular and Experimental Medicine, The Scripps Research Institute, SBR7, Rm. SR311, 10550 North Torrey Pines Road, 92037, La Jolla, CA, USA

    Peter K. Vogt Ph.D.

  2. Department of Molecular Medicine, MB-7, The Scripps Research Institute, 10550 North Torrey Pines Road, 92037, La Jolla, CA, USA

    Steven I. Reed Ph.D.

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Kamb, A. (1998). Cyclin-Dependent Kinase Inhibitors and Human Cancer. In: Vogt, P.K., Reed, S.I. (eds) Cyclin Dependent Kinase (CDK) Inhibitors. Current Topics in Microbiology and Immunology, vol 227. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-71941-7_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-71941-7_7

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-71943-1

  • Online ISBN: 978-3-642-71941-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation